Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03905707 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
A Phase 3 study of Short Bowel Syndrome, sponsored by Zealand Pharma.
- Active
- Registry status
- Phase 3
- Development phase
- 145
- Enrollment target
- 20
- Study locations
NCT03905707: Active Phase 3 study of Short Bowel Syndrome, sponsored by Zealand Pharma.
NCT03905707 is a Phase 3 study of Short Bowel Syndrome that is active but no longer recruiting, run by Zealand Pharma. The registered enrollment target is 145 participants, below the 176-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (18% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03905707, a Phase 3 study of Short Bowel Syndrome, is active but no longer recruiting, sponsored by Zealand Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 145 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the trial is to evaluate the long-term safety of glepaglutide treatment in patients with short bowel syndrome (SBS). Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
Primary Outcome
Incidence and type of Adverse Events
Conditions Studied
Interventions
- DRUG glepaglutide
Study Locations (20)
Other
- UZ Leuven - Leuven
- The Royal Alexandra Hospital - Edmonton
- Western University - London
- University Health Network - Toronto General Hospital - Toronto
- Rigshospitalet - Copenhagen
- Hôpital Beaujon - Clichy
- Centre Hospitalier Lyon-Sud - Pierre-Bénite
- Charité - Universitätsmedizin Berlin - Berlin
- Universitätsklinikum Bonn - Bonn
- Universitätsklinikum Frankfurt - Med. Klinik I - Frankfurt
- Asklepios Kliniken Hamburg GmbH - Hamburg
- Universitätsmedizin Rostock - Rostock
- UMC Radboud Nijmegen - Nijmegen
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Illinois
- University of Chicago Children's Hospital - Chicago
Minnesota
- Mayo Clinic College of Medicine - Rochester
Nebraska
- University of Nebraska Medical Center - Omaha
New York
- Mount Sinai Hospital - New York
Ohio
- Cleveland Clinic - Cleveland
Tennessee
- Vanderbilt University Medical Center, Nashville - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2019-05-07 |
| Est. Completion | 2026-04 |
| Phase | Phase 3 |
What the registry record for NCT03905707 still lists
NCT03905707 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, below the 176-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (18% lower).
The record links to 1 condition, with Short Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which glepaglutide is the first listed.
NCT03905707 names 20 study sites across 8 states, led by Other, District of Columbia, Illinois.
Frequently Asked Questions
What is clinical trial NCT03905707 about?
NCT03905707 is a clinical study titled "Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS". The primary objective of the trial is to evaluate the long-term safety of glepaglutide treatment in patients with short bowel syndrome (SBS). Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
What is the current status of trial NCT03905707?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 145 participants. The study started on 2019-05-07. Estimated completion is 2026-04.
What conditions does trial NCT03905707 study?
This clinical trial studies the following conditions: Short Bowel Syndrome.
What interventions are being tested in trial NCT03905707?
The interventions under investigation include: glepaglutide (DRUG).
Who is sponsoring clinical trial NCT03905707?
This trial is sponsored by Zealand Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03905707 being conducted?
This trial has 20 study locations across District of Columbia, Illinois, Minnesota, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Short Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03905707's enrollment target sits among peer trials
145 4th of 17 higher than 14 of 17 other Short Bowel Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Short Bowel Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
RECRUITING · Phase 3
-
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial
ACTIVE NOT RECRUITING · Phase 3
-
Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
ACTIVE NOT RECRUITING · Phase 3
-
Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF
COMPLETED · Phase 3
-
Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome
COMPLETED · Phase 3
-
Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI